Grail (NASDAQ:GRAL) Shares Down 4.5% - Should You Sell?

Shares of Grail, Inc. (NASDAQ:GRAL - Get Free Report) fell 4.5% during mid-day trading on Monday . The stock traded as low as $28.32 and last traded at $28.40. 246,749 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 1,222,546 shares. The stock had previously closed at $29.74.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their price objective on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday.

Grail Trading Up 6.8 %

The company has a fifty day simple moving average of $32.61 and a two-hundred day simple moving average of $21.67.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. As a group, equities analysts expect that Grail, Inc. will post -15.15 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $56,659.20. Following the transaction, the chief financial officer now owns 335,170 shares in the company, valued at approximately $10,457,304. This represents a 0.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the transaction, the chief executive officer now owns 828,662 shares in the company, valued at approximately $25,862,541.02. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,550 shares of company stock worth $360,436 in the last quarter.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GRAL. Douglas Lane & Associates LLC acquired a new position in shares of Grail in the 4th quarter valued at $3,034,000. A. D. Beadell Investment Counsel Inc. acquired a new position in shares of Grail in the 4th quarter valued at $430,000. FNY Investment Advisers LLC acquired a new stake in Grail during the 4th quarter worth $26,000. 180 Wealth Advisors LLC acquired a new stake in Grail during the 4th quarter worth $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management acquired a new stake in Grail during the 4th quarter worth $387,000.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.